All articles by Allie Nawrat

Allie Nawrat

Q&A with N-SIDE’s Sébastien Coppe: how digitisation overcomes clinical bottlenecks

The Covid-19 pandemic has transformed clinical development. Rather than taking ten years to bring a drug to market, vaccine manufacturers showed a drug can be developed, trialled and commercialised in less than a year. N-SIDE’s Sébastien Coppe explains the role technology and digitisation played in accelerating Covid-19 clinical development timelines and how future clinical trials will benefit from the lessons of the pandemic.

Treatment-resistant rare diseases: exploring landmark drug approvals in 2020

Rare disease drug development poses such serious challenges that only 5% of rare diseases have a treatment. However, this troubling situation is improving slowly due to better communication between all the stakeholders involved in research – patients, pharma companies, doctors and regulators. Allie Nawrat looks at three ground-breaking drugs that have been approved in the US this year, despite the distractions of the Covid-19 pandemic.

Coronavirus company news summary

16 April 2020 Japan’s Fujifilm has expanded manufacturing capacity to boost production of its influenza drug Avigan that is being…

Aligos to leverage Luxna’s tech to create anti-viral drugs

Aligos Therapeutics has broadened its license agreement with Osaka University’s Luxna Biotech to develop anti-viral drugs against the virus causing…

Exploring efficiencies from eTMF with Cancer Research UK

Creating electronic versions of documents and processes underlying clinical trials is becoming the norm. Cancer Research UK’s Stephen Nabarro walk us through its implementation of Veeva Vault eTMF two years ago, focusing on the challenges and efficiency benefit it has brought to the charity in its clinical trials work.

FDA accepts BLA from AstraZeneca and Daiichi for targeted chemotherapy

AstraZeneca and Daiichi Sankyo have announced that the US Food and Drug Administration (FDA) has accepted their biologics license application (BLA) for targeted cytotoxic chemotherapy trastuzumab deruxtecan.

Combining antibiotics with immune response to treat antibiotic resistant bacteria

Researchers from Lehigh University in the US have designed a new possible solution for antibiotic resistant bacteria by combining antibiotics with the exploitation of the body’s immune response.